Monte Rosa Therapeutics Q2 Collaboration Revenue Surges

Monte Rosa Therapeutics reported a surge in Q2 collaboration revenue. The company also announced the first subjects dosed in a Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader for the treatment of multiple inflammatory diseases. Additionally, Monte Rosa presented preclinical data at the American Association for Cancer Research Annual Meeting 2025 on the potential of its Cdk2-directed molecular glue degrader to treat HR-positive/HER2-positive breast cancer.

Monte Rosa Therapeutics (Nasdaq: GLUE) reported a significant increase in collaboration revenue during the second quarter of 2025, reaching $23.2 million compared to $4.7 million in the same period last year [1]. The company also announced the first subjects dosed in a Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader (MGD) for the treatment of multiple inflammatory diseases driven by the NLRP3 inflammasome, IL-1β, and IL-6 [2].

The Phase 1 study of MRT-8102, which is the only clinical-stage MGD that selectively degrades NEK7, includes single ascending dose (SAD) and multiple ascending dose (MAD) cohorts in healthy volunteers, as well as an additional cohort designed to evaluate potential early proof of concept in subjects with increased cardiovascular disease (CVD) risk and elevated C-reactive protein (CRP) [2]. Initial data from this study are expected in the first half of 2026.

In addition to the Phase 1 study of MRT-8102, Monte Rosa presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2025 on the potential of its CDK2-directed molecular glue degrader, MRT-51443, to treat HR-positive/HER2-negative breast cancer [2]. The data highlighted the potential of MRT-51443 to address a poorly addressed therapeutic target in breast cancer.

Monte Rosa's strong cash position, totaling $295.5 million as of June 30, 2025, is expected to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts [2]. The company also announced that it is on track to report additional clinical data for MRT-2359, a GSPT1-directed MGD for MYC-driven solid tumors, later this year.

References:
[1] Reuters. (2025, August 07). Monte Rosa Therapeutics Q2 net income USD -12.295 million. Retrieved from https://www.tradingview.com/news/reuters.com,2025-08-07:newsml_PLX705460:0-brief-monte-rosa-therapeutics-q2-collaboration-revenue-usd-23-194-million/
[2] Morningstar. (2025, August 07). Monte Rosa Therapeutics announces second-quarter 2025 financial results and business updates. Retrieved from https://www.morningstar.com/news/globe-newswire/9507677/monte-rosa-therapeutics-announces-second-quarter-2025-financial-results-and-business-updates